Please login to the form below
situximab
This page shows the latest situximab news and features for those working in and with pharma, biotech and healthcare.
EMA backs Janssen rare disease drug for approval
Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.
Latest news
-
Boehringer/Lilly's empagliflozin among CHMP recommendations
There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Consultant
-
competitive salary
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
-
Vice President
-
Competitive Salary Offered
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
Subscribe to our email news alerts
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- Genital herpes vaccine candidate heads for human studies
- Bayer bulks up in women’s health again with non-hormonal contraceptive deal
- FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
- Pfizer signs $507m cancer deal with Effector Therapeutics
- Key success factor (KSF)
- How do companies prepare for reimbursement?
- Lucid Group adds more magic to the mix with four new hires
- Communiqué Awards 2020 is now open for entry
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
PMHub
huumun formerly PharmiWeb Solutions
huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...
Latest intelligence
- How do companies prepare for reimbursement?
- Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
- Integrating electronic health records into clinical trials
- How organisations are working to realise the research potential of EHRs...
- Keeping up the fight against HIV and using the lessons to tackle other threats
- Danny Buckland interviews Gilead’s Mike Elliott...
Quick links
Infographics
